

vCLAS™ A New Benchmark in Ventricular Tachycardia Ablations

- Durable lesions of titratable depth and size
- Endocardial ablations of mid-myocardial scar
- Catheter stability during energy delivery
- Time-efficient procedures with few lesions
- No need for irrigation



MAEs 0% ACUTE SUCCESS 94%

REDEFINING RISK/BENEFIT
FOR VT ABLATION PATIENTS

*Adagio Medical, Inc. CryoCure-VT Interim Clinical Investigation Report. CS-191. Data on File.



vCLAS™ Cryoablation Catheter and Cryoablation Console are CE marked

INTENDED USE: The vCLAS™ Cryoablation Catheter, a component of the Adagio Medical Inc. VT Cryoablation System is intended to create transmural linear and focal lesions to cardiac structures within the endocardium of the ventricles with cryoablation.
INDICATIONS FOR USE: The Adagio Medical Inc. VT Cryoablation System (Catheter and Console) is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias.

VT Cryoablation System is an investigational device in the U.S.A.

INTENDED USE: The Adagio Medical Inc. VT Cryoablation System is intended to create transmural linear and focal lesions to cardiac structures within the endocardium of the ventricles with cryoablation.
INDICATIONS FOR USE: The Adagio Medical Inc. VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias.

vCLAS™ Cryoablation Catheter and Cryoablation Console are CE marked
VT Cryoablation System is an investigational device in the U.S.A. IDE # G220229



World Wide Headquarters
Adagio Medical, Inc
26051 Merit Circle, Suite #102
Laguna Hills, CA 92652

© 2024. Adagio Medical, Inc.
www.AdagioMedical.com

Europe
Adagio Medical GmbH
Rudolf-Diesel-Ring 27
83607 Holzkirchen, Germany

MKT-086 Rev. B



vCLAS™
DURABLE • DEPENDABLE • SAFE




**ULTRA-LOW TEMPERATURE
CRYOABLATION (ULTC)**

The Coolest Catheter Ablation Technology


ULTRA-LOW TEMPERATURE CRYOABLATION OF VENTRICULAR TACHYCARDIAS

vCLAS Ultra-Low Temperature Cryoablation (ULTC) system utilizes -196°C nitrogen to rapidly freeze myocardial tissue to form extensive and durable endocardial lesions, required for successful ablation of scar-related monomorphic ventricular tachycardias in patients with ischemic and non-ischemic cardiomyopathy.

ULTC ENERGY DELIVERY AND ICE-BALL FORMATION



LESION SIZE



*Images courtesy of Dr. Thomas Dewland




CATHETER SPECIFICATIONS

- 15 mm long cryoablation element
- 8 electrodes
- Bidirectionally deflectable
- 9 Fr OD

Easy Integration into the Standard Workflow of the EP Laboratory

FLEXIBLE ACCESS


- The catheter is compatible with 10 Fr deflectable and fixed-curve introducer sheaths




EAM AND EP SYSTEMS COMPATIBILITY

- Plugs into standard junction box
- Impedance-based electroanatomic tracking

ADOPTION INTO A VARIETY OF ABLATION STRATEGIES



Targeted Ablation



Substrate Homogenization

LESION DEPTH TITRATION BY FREEZE DURATION

- Acute lesion depth estimate
- Lesion depth is provided for Freeze, Thaw, Freeze ablation cycle.

*Images courtesy of Dr. Atul Verma, Dr. Tom De Potter and Dr. Vidal Essebag.

Adagio VT Cryoablation System Lesion Depth & Size Guidance Clinical Recommendation			
Freeze Duration	Target Depth*	Width**	Length
30 sec	< 4 mm	6 - 8 mm	15 mm At longer durations lesion length may extend beyond the ablation element.
60 sec	4 - 6 mm	9 - 10 mm	
120 sec	7 - 9 mm	11 - 12 mm	
180 sec	10+ mm	12+ mm	
Cryoablation element size: 15mm x 3mm			

* Freezes up to 300 sec has been clinically shown as safe in tissue depth > 10 mm but the therapeutic benefit has not been established.
** Provided for reference only. Ensure sufficient distance to temperature-sensitive cardiac structures.

Adagio Medical, Inc. QVR-400A. Data on File.

Promising Safety and Clinical Effectiveness Data

ACUTE EFFECTIVENESS

ELIMINATION OF INDUCIBLE CLINICAL VTs

94%

PATIENTS

97%

MORPHOLOGIES

SAFETY

0%
MAEs

PROCEDURAL CHARACTERSTICS

Average Procedure Time
185 Minutes

Average # of lesions 9

*Adagio Medical, Inc. CryoCure-VT Interim Clinical Investigation Report. CS-191. Data on File.